Publisher's Synopsis
Migraine is a worldwide ailment with considerable socio-economic impact. Although its pathogenetic mechanisms continue to elude understanding and are explained by conflicting theories, great progress has been made in the management of migraine through the development of effective medication.;This publication summarizes international experience with the newly introduced agent sumatriptan. It provides guidelines for the identification of migraine and its differentiation from other headache syndromes, and discusses diagnostic and therapeutic pitfalls. The epidemiology of migraine is examined in detail with emphasis on its social and economic impact. Current treatments for migraine are critically reviewed with reference to clinical trials in the international literature. Finally, the clinical profile of sumatriptan is discussed with regard to its efficacy, its role in cluster headache, and its safety and tolerability. Among the contributing authors to this issue are several key experts responsible for the development of sumatriptan and its clinical assessment. The comprehensive and practical nature of this publication makes it invaluable for any physician who diagnoses and treats patients with migraine.
